TY - JOUR
T1 - Extracorporeal photopheresis with TC-V in Japanese patients with steroid-resistant chronic graft-versus-host disease
AU - Okamoto, Shinichiro
AU - Teshima, Takanori
AU - Kosugi-Kanaya, Mizuha
AU - Kahata, Kaoru
AU - Kawashima, Naomi
AU - Kato, Jun
AU - Mori, Takehiko
AU - Ozawa, Yukiyasu
AU - Miyamura, Koichi
N1 - Funding Information:
Funding This study was sponsored by Therakos Inc., a Mallinckrodt Pharmaceuticals company. Vorpal Technologies KK, an independent contract research organization, was solely responsible for the administration of the clinical trial and the verification of the data points. A representative of Mallinckrodt Pharmaceuticals was a member of the steering committee but did not participate in the design of the study. Thomas Chin, of Mallinckrodt Pharmaceuticals, was responsible for the statistical analysis; however, he neither participated in the verification of the data from the investigational sites (performed by Vorpal Technologies KK) nor in the data interpretation or the writing of this manuscript. We thank Vorpal Technologies KK for their role in the conduct of the study. We also thank Gail Flores, PhD, and Brian Bass, both of Bass Global, Inc., for medical writing and editorial assistance with this manuscript, which was financed by Mallinckrodt Pharmaceuticals. Finally, we thank all of the patients who participated in this study.
Funding Information:
All patients received an explanation of the clinical study and provided written informed consent. The study was approved by the institutional review board of each institute and conducted in conformity with the Declaration of Helsinki. The clinical trial registration number is UMIN000014634. This study was sponsored by Vorpal Technologies KK, with the goal of gaining approval by the Japanese government.
Publisher Copyright:
© 2018, The Japanese Society of Hematology.
PY - 2018/9/1
Y1 - 2018/9/1
N2 - There are few established therapies for chronic graft-versus-host disease (cGVHD) refractory to first-line treatment with steroids. We evaluated the efficacy and safety of extracorporeal photopheresis (ECP) with a third-generation TC-V device in Japanese patients with cGVHD. Fifteen patients with steroid-resistant or -intolerant cGVHD after allogeneic hematopoietic stem cell transplantation participated in this multicenter open-label study. Extracorporeal photopheresis was conducted on days 1–3, week 1; days 1–2, weeks 2–12; and days 1–2, weeks 16, 20, and 24. The composite primary endpoint consisted of evaluation of response and changes in steroid dose 24 weeks after ECP initiation. Secondary endpoints included response over time, concomitant drug dose, quality of life, and safety. Twelve patients completed scheduled ECP therapy; eight (66.7%) showed a response at week 24. In all 15 patients, the mean (± standard deviation) steroid dose decreased 0.115 ± 0.230 mg/kg/day from screening to week 24. Five serious, potentially treatment-related adverse events (heart failure, thrombosis in the device, pneumonia, edema, and wheezing) occurred; none were fatal. This study confirmed that ECP using the TC-V device was effective, with an acceptable toxicity profile. Further studies in larger cohorts are clearly warranted to determine its optimal use in Japanese patients with cGVHD.
AB - There are few established therapies for chronic graft-versus-host disease (cGVHD) refractory to first-line treatment with steroids. We evaluated the efficacy and safety of extracorporeal photopheresis (ECP) with a third-generation TC-V device in Japanese patients with cGVHD. Fifteen patients with steroid-resistant or -intolerant cGVHD after allogeneic hematopoietic stem cell transplantation participated in this multicenter open-label study. Extracorporeal photopheresis was conducted on days 1–3, week 1; days 1–2, weeks 2–12; and days 1–2, weeks 16, 20, and 24. The composite primary endpoint consisted of evaluation of response and changes in steroid dose 24 weeks after ECP initiation. Secondary endpoints included response over time, concomitant drug dose, quality of life, and safety. Twelve patients completed scheduled ECP therapy; eight (66.7%) showed a response at week 24. In all 15 patients, the mean (± standard deviation) steroid dose decreased 0.115 ± 0.230 mg/kg/day from screening to week 24. Five serious, potentially treatment-related adverse events (heart failure, thrombosis in the device, pneumonia, edema, and wheezing) occurred; none were fatal. This study confirmed that ECP using the TC-V device was effective, with an acceptable toxicity profile. Further studies in larger cohorts are clearly warranted to determine its optimal use in Japanese patients with cGVHD.
KW - Chronic graft-versus-host disease
KW - Extracorporeal photopheresis (ECP)
KW - Hematopoietic stem cell transplantation
KW - Steroid resistant
UR - http://www.scopus.com/inward/record.url?scp=85049147154&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85049147154&partnerID=8YFLogxK
U2 - 10.1007/s12185-018-2483-6
DO - 10.1007/s12185-018-2483-6
M3 - Article
C2 - 29959747
AN - SCOPUS:85049147154
SN - 0925-5710
VL - 108
SP - 298
EP - 305
JO - International Journal of Hematology
JF - International Journal of Hematology
IS - 3
ER -